Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • O'Malley, FP
  • Chia, S
  • Tu, D
  • Shepherd, LE
  • Levine, Mark Norman
  • Huntsman, DG
  • Bramwell, VH
  • Andrulis, IL
  • Pritchard, KI

publication date

  • June 20, 2006